| Trial ID: | L6402 |
| Source ID: | NCT00813228
|
| Associated Drug: |
Sitagliptin (Januvia)
|
| Title: |
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 1|Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Sitagliptin (Januvia)
|
| Outcome Measures: |
Primary: Changes in plasma TGF-Beta 1 levels. | Secondary: Changes in plasma or stimulated PBMC cytokines levels, changes in stimulated PBMC proliferation, changes in peripheral blood gene expression and changes in immune phenotyping.
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
76
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT
|
| Start Date: |
2009-01-06
|
| Completion Date: |
2019-11-26
|
| Results First Posted: |
|
| Last Update Posted: |
2019-11-29
|
| Locations: |
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00813228
|
